Abstract Alu sequences are short, interspersed elements that have generated more than one million copies in the human genome. They propagate by transcription followed by reverse transcription and integration, causing mutations, recombination, and changes in pre-mRNA splicing. We have recently identified a 345-bp long Alu Ya5 element inserted in codon 650 within exon 11 of the chloride channel ClC-5 gene (CLCN5) of a patient with Dent's disease. A microsatellite pedigree analysis indicated that the insertion occurred in the germline of the maternal grandfather. Dent's disease is an X-linked renal tubular disorder characterized by low-molecularweight proteinuria, hypercalciuria, nephrolithiasis, and nephrocalcinosis. Here, we found, by RT-PCR amplification of RNA extracted from the patient's blood and subsequent DNA sequencing, that the Alu insertion led to an aberrant splicing of the CLCN5 pre-mRNA that skipped exon 11. Using the ESE finder and RESCUE-ESE Web interfaces, we identified two high-score exonic splicing enhancer (ESE) sequences in the site of insertion. The functional significance of these ESE motifs is suggested by our observation that these sequences are highly conserved among mammal CLCN5 genes. Therefore, we suggest that the Alu insertion causes exon skipping by interfering with splicing regulatory elements.
Introduction
Alu elements are short sequences of DNA that generate new copies of themselves by reverse transcription of an Alu-derived RNA polymerase III transcript (Batzer and Deininger 2002) . The human genome contains $1.4 million Alu copies, which are commonly found in the noncoding regions of genes, such as 5¢ and 3¢ UTRs and introns (Jurka 1998; International Human Genome Sequencing Consortium 2001) . Genetic diseases can result from different types of mutations caused by the insertion of an Alu sequence. Examples include neurofibromatosis, Apert syndrome, hemophilia, familial hypocalciuric hypercalcemia, breast cancer, hereditary nonpolyposis colorectal cancer, and Hunter's disease (Ostertag and Kazazian 2001; Ganguly et al. 2003; Ricci et al. 2003; Kloor et al. 2004) . Recent work by Lev-Maor et al. (2003) has shown that intronic Alu sequences can be included into mature mRNAs via a splicing-mediated process termed exonization, which can result in human disease or contribute to humanspecific protein diversity.
Recently, we identified an Alu insertion in exon 11 of the CLCN5 gene in a patient with Dent's disease . Sequence analysis showed that the Alu element is inserted in the same orientation as the CLCN5 gene (Fig. 1a) and is closely related to the AluYa5 subfamily ). Dent's disease is a renal tubular disorder characterized by low-molecular-weight proteinuria, hypercalciuria, nephrocalcinosis, nephrolithiasis, rickets, and eventual renal failure (OMIM: 300009; Lloyd et al. 1996) . This disease is caused by mutations in the CLCN5 gene that encodes the voltage-gated chloride channel ClC-5 (Fisher et al. 1995; Lloyd et al. 1996; Carballo-Trujillo et al. 2003) although recent findings have shown that mutations in the OCRL1 gene, also involved in proximal tubular function, are responsible for the disease phenotype in some patients (Hoopes et al. 2005) . Studies with ClC-5 knockout mice showed that loss of ClC-5 function results in an endosomal acidification defect and reduced proximal tubular protein reabsorption, which explain the symptoms of Dent's disease (Piwon et al. 2000) .
Based on the results obtained with the Alu insertion mutation in BRCA2 (Miki et al. 1996) , we suggested that the Alu insertion in CLCN5 might cause skipping of exon 11 . In this study, we show that the CLCN5 Alu insertion resulted in altered splicing that skipped exon 11 in the patient's blood cells. Analysis of the insertion site suggests that the Alu element disturbs two highly conserved exonic splicing enhancer (ESE) motifs.
Material and methods
The clinical and biochemical characteristics of the patient have been previously described . The diagnosis of Dent's disease was based on the presence of hypercalciuria and microproteinuria and was then confirmed by the identification of the mutation in the CLCN5 gene. To date, the patient does not show nephrolithiasis or nephrocalcinosis and is being treated with hydrochlorothiazide and amiloride. Analysis of the patient's pedigree indicated that apart from the patient, only the patient's mother carries the mutation . Furthermore, a polymorphism analysis indicated that the Alu insertion found in CLCN5 was originated in the germline of the maternal grandfather . Both of his parents and his sister had hypercalciuria, and his mother had moderate proteinuria, but there was no history of urolithiasis or Dent's disease in the family, including the maternal grandfather . As the proband was a minor, parents gave informed consent for this study.
Total RNA was isolated from whole blood samples using the PAXgene Blood RNA System (Qiagen), and digested with RNase-free DNase I. Kidney poly A + RNA (Clontech) and total RNA from blood were reverse transcribed with random hexamers using the First-strand cDNA synthesis kit (Roche). Two microliters of cDNA were then used as a template for PCR amplifications with the following profile: an initial denaturation step at 94°C for 2 min, followed by 35 cycles of amplification (94°C for 20 s, 60°C for 20 s, 72°C for 20 s), and an extension at 72°C for 5 min. Thermocycling was performed on a GeneAmp PCR system 9700 (Applied Biosystems). The region spanning CLCN5 exons 2-12 was amplified in three overlapping fragments using pairs of primers designed from the coding region (Table 1) . To study the effect of the exon 11 Alu insertion on pre-mRNA splicing, we amplified a segment of CLCN5 cDNA starting in exon 10 and finishing in exon 12 using primers CLCN510F and CLCN5cDN 12R (Table 1 ). These two primers were also used to amplify genomic DNA from blood of the patient and a healthy individual.
DNA sequencing of amplified PCR products was carried out directly on both strands using the Big Dye Terminator kit v 3.0 with an ABI PRISM 310 Genetic Analyzer (Applied Biosystems). The primers used for sequencing were the same primers used for PCR amplification.
Both ESE finder (Cartegni et al. 2003) and RESCUE-ESE (Fairbrother et al. 2002) Web interfaces were used to search the human wild-type (NM_000084), mutant , rabbit (AF195523), mouse (NM_016691), rat (NM_017106), and pig (NM_214139) exon 11 sequences for the presence of ESE motifs. ESE finder was used with a threshold value of 3.0 for all four types of ESE motifs.
Results and discussion
The entire coding region of CLCN5 (exons 2-12) was amplified in three overlapping RT-PCR reactions using RNA isolated from blood of a healthy individual and kidney poly A + RNA (Clontech). The same expectedsize products were observed in both the blood and the kidney RNA samples (results not shown). Forino et al. (2004) have also shown that the CLCN5 splicing patterns in leukocytes and kidney biopsies of normal individuals are the same. We therefore considered that blood cells were a suitable source of RNA to study the effect of CLCN5 mutations on pre-mRNA splicing.
PCR amplification of blood DNA from the patient with primers specific for exons 10 and 12 showed the presence of a 2,164-bp band instead of the normal 1,819-bp fragment, confirming the presence of the Alu insertion in the patient's CLCN5 gene (Fig. 1b) . RT-PCR analysis of the patient's RNA with the same primers showed a unique band of 205 bp instead of the full-length 422-bp band observed with the healthy individual, suggestive of an exon skipping event (Fig. 1c) . A larger band(s) containing Alu sequences was not observed even after increasing the number of PCR cycles (results not shown). The same RT-PCR analysis using RNA from the heterozygous mother yielded the band corresponding to the truncated fragment, a faint 422-bp band (confirmed by further amplification and DNA sequencing as the wild-type fragment), and a another faint band of approximately 470 bp (Fig. 1c) . Attempts to sequence this larger band were unsuccessful. We then sequenced the 205-bp RT-PCR products in order to identify which DNA sequences were missing. The results showed that the abnormal fragment lacked the entire exon 11 (217 bp) and contained the sequences expected from exons 10 and 12 precisely spliced together (Fig. 1d) . This loss changes the open reading frame of the CLCN5 transcript and adds 12 new codons (GDCLESLPKRMC) to the 3¢ end of codon 644 followed by a premature stop codon. The predicted truncation removes 102 amino acids from the carboxy terminus of the ClC-5 protein, including the second CBS (cystathionine-betasynthase) motif, CBS2, and the PY motif (Fig. 1e) . Tandem pairs of conserved CBS motifs are found in a wide variety of proteins and associate to form Bateman domains (Bateman 1997) . A recent study reveals that these domains bind adenosine derivatives (Scott et al. 2004) , and the authors suggest that the binding of ATP to the CBS motifs of CLC chloride channels is necessary before the channels will open. Furthermore, heterologous expression studies in mammalian cells have shown that the CBS2 domain of ClC-1, a channel related to ClC-5, is critical for channel function (Hebeisen et al. 2004) . The sequence located between the CBS domains of ClC-5 contains a PY sorting signal motif. Schwake et al. (2001) have found that alteration of this internalization motif leads to increased plasma membrane expression of ClC-5. These findings illustrate the importance of the carboxy terminus of CLC channels. Also, Hryciw et al. (2003) have found that the ClC-5 carboxy terminus binds to cofilin, a protein necessary for endocytosis.
The analysis of the CLCN5 genomic region, including the Alu insertion, with three available programs to define protein coding regions, yielded different splicing patterns, but none of them predicted a complete skipping of exon 11 (results not shown). In order to explain the cause of exon skipping due to the Alu insertion, we searched the sequence of the 5¢ end of exon 11 for the presence of potential ESE motifs. These motifs are CLCN5cDN 2F  GACTTCTTGGAGGAGCCAATC  2  441  CLCN5cDN 5R  GAGAGCCCAGAGGACGTACA  5  CLCN5cDN 5F  GGCTCTCCTATTTGCCTTCC  5  751  CLCN5cDN 8R  GTCCAGAAGGCCACAGTCAT  8  CLCN5cDN 8F  GGCAGCTGGCTTTAACACTC  8  985  CLCN5cDN 12R  TCCCGCTTTACATCCAGAAC  12  CLCN510F  TACAGTGGCTTCCCAGTGGT  10  422  CLCN5cDN 12R  TCCCGCTTTACATCCAGAAC  12 binding sites for essential splicing factors, the serine/ arginine-rich (SR) proteins that play an important role in exon recognition during pre-mRNA splicing (Cartegni et al. 2002; Ca´ceres and Kornblihtt 2002) . Using the ESE finder software, we found that the Alu element, inserted 15 nucleotides from the 5¢ end of exon 11, is within a high-score ESE sequence (AAACAGG) that is likely bound by the SRp40 protein (Fig. 2a) . Furthermore, the Alu insert creates a longer distance between an overlapping SF2/ASF ESE motif (AACAGGA) and the 5¢ end of exon 11. Several studies suggest that functional ESEs occupy specific positions relative to the splice sites of an exon (Cartegni et al. 2002; Fairbrother et al. 2004) . The alignment of CLCN5 exon 11 from humans, rabbit, mouse, rat, and pig showed that the SRp40 and SF2/ ASF ESE sequences close to the 5¢ end are identical (Fig. 2b) , indicating high conservation during evolution and a functional importance in splicing. The SRp40 and SF2/ASF ESE motifs strongly overlap (Fig. 2) , being unlikely that the two SR proteins bind simultaneously. Therefore, only one of these two sequences may represent a functional ESE, or the motifs may act as enhancers in a mutually exclusive manner, depending on the individual pre-mRNA molecule or cell type (Ca´ceres and Kornblihtt 2002) . On the other hand, RESCUE-ESE identified six overlapping candidate ESEs in the 5¢ end of exon 11, five of which (AAAGAA, AAGAAA, AGA-AAC, GAAACA and AAACAG) were disturbed by the Alu insertion. As the sequence AAACAG was identified with both approaches, we suggest that the Alu mutation causes exon 11 skipping by altering the interaction between SRp40 and this ESE sequence. We cannot exclude the possibility that the CLCN5 Alu sequence, which is inserted in the same orientation as the gene , inhibits the pre-mRNA splicing by itself. However, a search in human genomic DNA libraries for sequences that inhibit splicing failed to find Alu sequences in the forward orientation (Fairbrother and Chasin 2000) . An Alu insertion in exon 22 of BRCA2 also results in exon skipping (Miki et al. 1996) . However, in this case the Alu element is inserted just downstream from the 3¢ end of two high-score ESE motifs, SRp40 and SF2/ASF (results not shown). Recently, Kloor et al. (2004) reported an Alu insertion in exon 6 of the MSH2 gene in a patient with hereditary nonpolyposis colorectal cancer syndrome. They did not observe exon skipping in the RNA from the patient's peripheral blood cells, but an analysis of MSH2 exon 6 with ESE finder showed that the Alu sequence was inserted within two overlapping high-score ESE motifs, SC35 and SRp40 (results not shown).
In conclusion, the CLCN5 Alu insertion caused skipping of exon 11 in pre-mRNA from blood as a result of the abnormal splicing, probably due to disruption of conserved ESEs. The altered splicing caused by the Alu insertion would predict a truncated ClC-5 protein that lacks part of the carboxy terminus, including the PY and CBS2 domains, critical for sorting and chloride channel function. Further investigations are needed to confirm the functional significance of the ESE in CLCN5 exon 11 and that the skipping also takes place in kidney cells. Fig. 2 Analysis of ESE sequences in exon 11 of CLCN5. a Potential ESE sequences within the first 38 nucleotides of the 5¢ end of exon 11 shown as histograms of scores for SRp40 (white), SF2/ ASF (gray), and SC35 (black) motifs. The arrowhead indicates the point of Alu insertion. Bases from the Alu sequence are underlined. b Partial sequence of human exon 11 compared with the corresponding sequence of other mammals. Boxes denote conserved potential ESE sequences for SRp40 (white) and SF2/ASF (gray) motifs. The dots indicate identical sequence y Salud FUNCIS and PI042620 from Fondo de Inversio´n Sanitaria to FCM and VGN. CF is a FUNCIS postdoctoral fellow.
